The clarithromycin tablets market has seen steady growth, projected to grow from $1.91 billion in 2023 to $2.09 billion in 2024 at a CAGR of 9.3%. Factors such as a global rise in infections, increased cases of helicobacter pylori, higher production of generics, a rise in respiratory diseases, and growth in skin and bacterial infections have supported this expansion.
The clarithromycin tablets market will reach $2.99 billion by 2028, growing at a CAGR of 9.4%. Growth is driven by the increasing prevalence of gastrointestinal infections, antibiotic resistance, and the rise of combination therapies. Trends include new formulations, generic versions, and technological advancements in manufacturing processes.
Major Driver In The Clarithromycin Tablets Market
The rising prevalence of respiratory infections is expected to drive the clarithromycin tablet market. The increase in respiratory infections is linked to rising air pollution, climate change, and pathogen spread. Clarithromycin tablets provide an effective treatment for bacterial infections. According to the National Health Service in September 2022, hospital admissions for asthma in the UK surged by 149%. The clarithromycin tablet market is expected to reach USD 1.87 billion in 2023, USD 2.02 billion in 2024, and USD 3.32 billion by 2028.
Request A Free Sample Of The Clarithromycin Tablets Market Report
Clarithromycin Tablets Market Competitive Landscape
AbbVie Inc., Bayer AG, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Cipla Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Medochemie Ltd., Takeda Pharmaceutical Company Ltd., Strides Pharma Science Ltd., LGM Pharma LLC, Envee Drugs Pvt. Ltd., SM Biomed Sdn Bhd, Wockhardt Ltd.
Key Clarithromycin Tablets Market Trend
Leading companies in the clarithromycin tablets market are introducing novel products, such as Vonoprazan tablets, for the treatment of Helicobacter pylori infection, to enhance eradication rates and address antibiotic resistance. Vonoprazan is a potassium-competitive acid blocker used for acid-related disorders. In October 2023, Phathom Pharmaceuticals, a US-based company, received FDA approval for the reformulation of vonoprazan tablets. This includes VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which combine vonoprazan with amoxicillin and clarithromycin to treat H. pylori infection in adults.
Purchase The Global Clarithromycin Tablets Market Report Directly And Get A Swift Delivery
Global Clarithromycin Tablets Market Segmentation
The clarithromycin tablets market covered in this report is segmented –
1) By Type: 250 mg Tablets, 500 mg Tablets
2) By Distribution Channel: Hospital Pharmacy, Online pharmacy, Retail pharmacy, Clinics
3) By Application: Dermatology, Ear, Nose, and Throat (ENT), Thoracic and Cardiovascular, Pediatric, Pulmonary Medicine
By Geography:The regions covered in the clarithromycin tablets market report areAustralia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the clarithromycin tablets market in 2023.
The Clarithromycin Tablets Global Market Report 2024 furnishes information about the global clarithromycin tablets market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.
